NuvOx Pharma Revenue and Competitors
Estimated Revenue & Valuation
- NuvOx Pharma's estimated annual revenue is currently $1.4M per year.
- NuvOx Pharma's estimated revenue per employee is $201,000
Employee Data
- NuvOx Pharma has 7 Employees.
- NuvOx Pharma grew their employee count by 17% last year.
NuvOx Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.2M | 36 | 6% | N/A | N/A |
#2 | $29.1M | 145 | 48% | N/A | N/A |
#3 | $1.2M | 6 | -50% | N/A | N/A |
#4 | $1.4M | 7 | 17% | N/A | N/A |
#5 | $5.8M | 29 | -29% | N/A | N/A |
#6 | $33.2M | 165 | 19% | N/A | N/A |
#7 | $41.8M | 208 | 16% | N/A | N/A |
#8 | $3.6M | 18 | -36% | N/A | N/A |
#9 | $7M | 35 | -10% | N/A | N/A |
#10 | $11.7M | 58 | -11% | N/A | N/A |
What Is NuvOx Pharma?
NuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a Phase IIa trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF). *Cover photo painting by Diane Fairfield
keywords:N/AN/A
Total Funding
7
Number of Employees
$1.4M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NuvOx Pharma News
alliance pharma plc, baxter, NuvOx Pharma, Sanguine Biosciences, Therapure Biopharma Inc, Hemarina, Hemoglobin Oxygen Therapeutics,...
NuvOx Pharma's technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role,...
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.5M | 7 | 0% | N/A |
#2 | $0.5M | 7 | 0% | N/A |
#3 | $1.1M | 7 | 0% | N/A |
#4 | $0.5M | 7 | 17% | N/A |
#5 | $1.1M | 7 | 17% | N/A |